Edesa Biotech, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
EDSA Nasdaq 2836 www.edesabiotech.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Edesa Biotech, Inc.

3 Small Cap Biotech Stocks Trading At A Discount With Late Stage Clinical Catalysts - Aug 27th, 2026 10:44 pm
EDSA: Recruitment in Phase 2 Vitiligo Study Set to Get Underway - Aug 24th, 2026 2:02 am
Edesa Biotech Stock Sinks After Fresh Capital Raise - Aug 20th, 2026 4:20 am
Edesa Biotech Announces Pricing of $25.0 Million Public Offering - Aug 19th, 2026 8:20 pm
Edesa Biotech Announces Proposed Public Offering - Aug 19th, 2026 2:01 pm
Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results - Aug 13th, 2026 2:15 pm
EDSA: Positive Exploratory Data in Patients with AKI - Jul 2nd, 2026 6:02 am
Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors - Jun 11th, 2026 7:15 am
Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury - Jun 5th, 2026 7:20 am
EDSA: Preparing for Mid-2026 Start to Phase 2 Vitiligo Trial - May 22nd, 2026 6:15 am
Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference - May 19th, 2026 7:15 am
Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results - May 14th, 2026 2:30 pm
Edesa Biotech Reaches US$68m Market Cap Benefiting Insider Stock Buying - Apr 23rd, 2026 4:49 am
Edesa Biotech (EDSA) Reaffirms 2026 Clinical Study Timeline for Vitiligo Treatment - Apr 20th, 2026 8:14 am
Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit - Mar 31st, 2026 2:20 pm
Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment - Mar 26th, 2026 7:15 am
EDSA: Strengthened Phase 3 ARDS Data Shows Significant Reduction in 28-Day Mortality - Mar 2nd, 2026 3:09 am
Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study - Feb 24th, 2026 7:15 am